Literature DB >> 24939558

Higher level of IL-6 in Jaccoud's arthropathy secondary to systemic lupus erythematosus: a perspective for its treatment?

Ajax Mercês Atta1, Rodrigo C Oliveira, Isabela S Oliveira, Mariana P Menezes, Taciana P S Santos, Maria Luiza B Sousa Atta, Mittermayer B Santiago.   

Abstract

Jaccoud's arthropathy (JA) is a condition characterized clinically by 'reversible' joint deformities along with an absence of articular erosions on a plain radiograph. The main clinical entity associated with JA is systemic lupus erythematosus (SLE) with a prevalence of around 5 %. The aim of the present study was to compare the inflammatory markers including cytokine levels in blood of SLE patients with and without JA. Patients with diagnosis of SLE as defined by ACR criteria were screened and divided in two groups, one with JA and one control group without JA. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complement C3 and C4 levels antinuclear antibodies (ANA), anti-dsDNA antibodies and serum levels of IL-2, IL-6, IL-10, IL-21, IL-22 and TNF-α were determined in all patients. Eighty female patients with SLE, 18 (22.5 %) with JA and 62 (77.5 %) without JA, were included in this study. JA patients had higher disease duration (p = 0.008), ESR (p < 0.001), CRP level (p = 0.002), ANA titer (p < 0.001) and dsDNA antibody level (p = 0.009). The serum levels of IL-2, IL-10, IL-21, IL-22 and TNF-α were not significantly different between the two groups (p > 0.05), but the level of IL-6 was higher in JA group (p < 0.001). The serum level of IL-6 might have a correlation with JA secondary to SLE.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24939558     DOI: 10.1007/s00296-014-3069-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  12 in total

Review 1.  Miscellaneous non-inflammatory musculoskeletal conditions. Jaccoud's arthropathy.

Authors:  Mittermayer B Santiago
Journal:  Best Pract Res Clin Rheumatol       Date:  2011-10       Impact factor: 4.098

2.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

3.  Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus.

Authors:  G Ø Eilertsen; C Nikolaisen; A Becker-Merok; J C Nossent
Journal:  Lupus       Date:  2011-03-21       Impact factor: 2.911

4.  Tenascin-X: a candidate gene for benign joint hypermobility syndrome and hypermobility type Ehlers-Danlos syndrome?

Authors:  M C Zweers; M Kucharekova; J Schalkwijk
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

5.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

6.  Jaccoud's arthropathy: proper classification criteria and treatment are still needed.

Authors:  Mittermayer B Santiago
Journal:  Rheumatol Int       Date:  2012-09-05       Impact factor: 2.631

7.  Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis.

Authors:  M Linker-Israeli; R J Deans; D J Wallace; J Prehn; T Ozeri-Chen; J R Klinenberg
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

8.  SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation.

Authors:  Z Touma; M B Urowitz; D Ibañez; D D Gladman
Journal:  Lupus       Date:  2011-01       Impact factor: 2.911

Review 9.  Jaccoud arthropathy in systemic lupus erythematosus: analysis of clinical characteristics and review of the literature.

Authors:  Mittermayer B Santiago; Verena Galvão
Journal:  Medicine (Baltimore)       Date:  2008-01       Impact factor: 1.889

10.  Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity?

Authors:  P E Spronk; E J ter Borg; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

View more
  1 in total

1.  Severe Jaccoud's arthropathy in systemic lupus erythematosus.

Authors:  Mittermayer B Santiago; Verena Galvão; Daniel Sá Ribeiro; Willer D Santos; Priscila R da Hora; Anna Paula Mota; Emanuela Pimenta; Isabela Oliveira; Ajax M Atta; Mitermayer G Reis; Eliana A G Reis; Carolina Lins
Journal:  Rheumatol Int       Date:  2015-08-27       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.